Medicine and Dentistry
Leuprorelin
100%
Patient
54%
Combination Therapy
45%
Prostate Cancer
36%
Pituitary Tumour
36%
Contraindication
27%
Surgery
18%
Radiation Therapy
18%
Pituitary Adenoma
18%
Microadenoma
18%
Injection
18%
Inpatient
18%
Magnetic Resonance Imaging
9%
Follow up
9%
Adverse Event
9%
Evaluation Study
9%
Apoplexy
9%
Brachytherapy
9%
Gonadotropin
9%
Growth
9%
Symptom
9%
Macroadenoma
9%
Biochemical Recurrence
9%
Hypophysis Apoplexy
9%
Gland
9%
INIS
patients
72%
therapy
45%
prostate
45%
cancer
36%
tumors
36%
radiotherapy
18%
injection
18%
evaluation
9%
nmr imaging
9%
surgery
9%
growth
9%
recovery
9%
management
9%
symptoms
9%
brachytherapy
9%
adenomas
9%
gonadotropins
9%
glands
9%
Pharmacology, Toxicology and Pharmaceutical Science
Leuprorelin
100%
Prostate Cancer
36%
Hypophysis Tumor
36%
Hypophysis Adenoma
18%
Microadenoma
18%
Adverse Event
9%
Cerebrovascular Accident
9%
Gonadotropin
9%
Macroadenoma
9%
Biochemical Recurrence
9%
Hypophysis Apoplexy
9%
Symptom
9%